Table 1.
Clinicopathological characteristics of cohorts A and triple-negative breast cancer cohort B
| Parameter | Cohort A | Cohort B (TNBC) |
|---|---|---|
| N (%) | N (%) | |
| All patients | 398 | 156 |
| Age, years | ||
| <50 | 124 (31.2) | 72 (46.15) |
| ≥50 | 257 (64.6) | 80 (50.1) |
| Unknown | 17 (4.3) | 4 (2.56) |
| Nodal status | ||
| Positive | 78 (19.6) | 15 (9.6) |
| Negative | 203 (51.0) | 39 (25) |
| Unknown | 117 (29.4) | 104 (66.6) |
| Tumor size | ||
| <2 cm | 217 (54.5) | 44 (28.2) |
| 2–5 cm | 73 (17.3) | 74 (47.43) |
| Unknown | 108 (27) | 38 (24.35) |
| Grade | ||
| 1–2 | 97 (24.37) | 45 (28.84) |
| 3 | 103 (25.87) | 78 (50.00) |
| NA/Unknown | 198 (49.7) | 32 (2) |
| ERα | ||
| Positive (1–3) | 264 (66.3) | |
| Negative (0) | 89 (22.3) | |
| Unknown | 45 (11.3) | |
| HER2 | ||
| Positive (3+) | 20 (5) | |
| Negative (0–1+) | 272 (68.3) | |
| Unknown/Equivocal | 106 (26.6) | |
| Adjuvant treatment | ||
| Hormonal only | 93 (23.4) | |
| Chemotherapy only | 72 (18.1) | |
| Hormonal+Chemo | 48 (12.1) | |
| None | 89 (22.4) | |
| Unknown | 96 (24.1) | |
| Follow-up (m) | ||
| Median (range) | 139 (3–385) | 52 (4–231) |
Abbreviations: ERα estrogen receptor alpha, NA not available, TNBC triple-negative breast cancer